Početna › Mijelofibroza › Massachusetts
Kliničke studije za Mijelofibroza u državi Massachusetts
13 studija za Mijelofibroza traži sudionike na lokacijama u državi Massachusetts.
Gradovi u državi Massachusetts
Službeni tekst studije (engleski)
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
- Massachusetts General Hospital, Boston
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 2. lis 2026. · NCT04176198A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
- Tufts Medical Center, Boston
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 1. lis 2026. · NCT07623161A Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 17. ruj 2026. · NCT06343805A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis
- Massachusetts General Hospital (Data Collection Only), Boston
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 28. srp 2026. · NCT06773195A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
- Brigham and Women's Hospital, Boston
U tijeku regrutacijaFaza 1Zdravi dobrovoljci dobrodošli
Od 18 do 75 godina · Oba spola · Ažurirano 28. srp 2026. · NCT07020533Study of INCA036978 in Participants With Myeloproliferative Neoplasms
- Massachusetts General Hospital, Boston
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 22. srp 2026. · NCT07441694Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
- Dana Farber Cancer Institute, Boston
U tijeku regrutacijaFaza 1
Od 13 godina i više · Oba spola · Ažurirano 5. svi 2026. · NCT04771572A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
- Dana Farber Cancer Institute, Boston
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 17. tra 2026. · NCT06034002Momelotinib During and After HCT in Myelofibrosis
- Massachusetts General Hospital, Boston
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 31. ožu 2026. · NCT07104799A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- Dana-Farber Cancer Institute, Boston
U tijeku regrutacijaFaza 2
Od 18 do 66 godina · Oba spola · Ažurirano 17. ožu 2026. · NCT06859424CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
- DFCI/BWH Brigham and Women's Hospital, Boston
U tijeku regrutacijaFaza 2Zdravi dobrovoljci dobrodošli
Od 18 do 75 godina · Oba spola · Ažurirano 10. ožu 2026. · NCT06059391SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Worcester
U tijeku regrutacijaOpažajna studija
Sve dobne skupine · Oba spola · Ažurirano 28. lis 2025. · NCT03452774Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
- Dana Farber Cancer Institute, Boston
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2025. · NCT06479135Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.